Merck KGaA Cancer Deal-Making Spree Continues With PDS Tie-Up
Licenses Promising Candidate For $5m Upfront
PDS is getting rights to Merck's M9241, a tumor-targeting interleukin-12 fusion compound which is a key component, together with its own investigational HPV16-targeted immunotherapy, in a triple combination being studied to treat advanced HPV-positive cancers.
